Skip to main content
. 2021 Jul 1;2(8):100205. doi: 10.1016/j.jtocrr.2021.100205

Figure 2.

Figure 2

Overall survival in patients with a PD-L1 TPS of ≥50% in patients (A) with and (B) without baseline brain metastases and in patients with a PD-L1 TPS of ≥1% in patients (C) with and (D) without baseline brain metastases. Four patients in the pooled intent-to-treat population had missing overall survival data. CI, confidence interval; HR, hazard ratio; PD-L1, programmed death-ligand 1; TPS, tumor proportion score.